 |
TSO3: Conference Call and Webcast - Financial Results for Q1 2007May 4, 2007Québec City, May 4, 2007 – TSO3 Inc. (“TSO3”) (TSX: TOS) announces today that it will report financial results for the first quarter 2007 ended March 31, on Friday, May 11, 2007. TSO3 will host a conference call and a webcast at 10:30 A.M. (ET), on May 11, 2007.Only analysts and institutional investors are invited to participate in this conference call. The numbers to dial for access are (514) 807-8791 (Montréal area), (416) 644-3429 (Toronto area) or the toll-free number 1-800-591-7539. Other Interested parties may listen to the live webcast of the conference call via TSO3’s Website. The webcast will be archived for 90 days. About TSO3 TSO3 is located in Québec City, Québec, Canada, and was founded in 1998. The Company’s mission is to develop and market innovative and comprehensive sterilization solutions. TSO3 has perfected an innovative sterilization process using ozone as the sterilizing agent. The first product based on this technological platform is the 125L Ozone Sterilizer, which is intended for hospital sterilization units. The 125L – named after its 125-litre/4.3-cubic-foot capacity – was designed to sterilize heat-sensitive surgical and diagnostic devices which are expensive and in high demand from the surgical suite. The ozone sterilization process is a safe, efficacious, fast and cost-effective response to evolving sterilization needs. The 125L Ozone Sterilizer by TSO3 has been cleared for commercialization by Health Canada and by the U.S. Food and Drug Administration (FDA). On August 3, 2006, the FDA authorized the utilization of the 125L Ozone Sterilizer for sterilizing a significantly broader range of lumened instruments that are longer and with smaller interior diameters. TSO3 currently has more than 60 employees, 23 of whom work in the sales and marketing team. The statements in this release and oral statements made by representatives of TSO3 relating to matters that are not historical facts (including, without limitation, those regarding the timing or outcome of any financing undertaken by TSO3) are forward-looking statements that involve certain risks, uncertainties and hypotheses, including, but not limited to, general business and economic conditions, the condition of the financial markets, the ability of TSO3 to obtain financing on favourable terms and other risks and uncertainties. The TSX has neither approved nor disapproved the information contained herein and accepts no responsibility for it.- 30 - Source: TSO3 Inc. Information: Mathieu Claise Interim Director, Corporate Communications and Investor Relations (418) 651-0003, Ext. 237 Email: ir@tso3.com |
© 2005-2008 TSO3. All Rights Reserved.
